Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: An analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial

Diabetes, Obesity and Metabolism

Volumn 12, Issue 1, 2010, Pages 26-34

  Van Gaal, L F ^a   Caterson, I D ^b   Coutinho, W ^c   Finer, N ^d   Maggioni, A P ^e   Sharma, A M ^f   Torp Pedersen, C ^g   Ge, H ^h   Moran, S A ^h   Shepherd, G M ^h   James, W P T ⁱ  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ANMCO RESEARCH CENTER   (Italy)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h ABBOTT LABORATORIES   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiobesity drugs; CVD risk factors; Diabetes; Obesity; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; INSULIN; MEGLITINIDE; PLACEBO; SIBUTRAMINE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 73349141156     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01090.x     Document Type: Article

References (27)

1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
2. Guidelines on diabetes, pre-diabetes and cardiovascular diseases; ESC and EASD guidelines. Eur Heart J 2007, 28:88-136.
3. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006, 8:206-213.
4. Sjöström L, Narbro K, Sjöström CD. Effects of bariatric surgery on mortality in Swedish obese patients. N Engl J Med 2007, 357:741-752. for the Swedish Obese Patients Study.
5. Adams TD, Gress RE, Smith SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753-761.
6. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008, 9:378-387.
7. Torp-Pedersen C, Caterson I, Coutinho W. Cardiovascular responses to weight management and sibutramine in high-risk patients: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-2923. on behalf of the SCOUT Investigators.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study Group
9. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007, 25:1105-1187.
10. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987, 10:563-566.
11. Bray GA, Blackburn GL, Ferguson JM. Sibutramine produces dose-related weight loss. Obes Res 1999, 7:189-198.
12. 53. http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf, National Institute for Health and Clinical Excellence, Clinical Guideline 43 (CG 43). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. December 2006. Available from URL, pg., Accessed December 2008
13. Dixon JB, O'Brien PE, Playfair J. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomised controlled trial. JAMA 2008, 299:316-323.
14. Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. for The Finnish Diabetes Prevention Study Group.
15. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. The Diabetes Prevention Programme Research Group
16. Balkau B, Deanfield JE, Despres J-P. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries. Circulation 2007, 116:1942-1951.
17. Yusuf S, Hawken S, Ounpuu S. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649. and the INTERHEART Study Investigators.
18. Ross R, Janssen I, Dawson J. Exercise with or without weight loss is associated with reduction in abdominal and visceral obesity in women. A randomised controlled trial. Obese Res 2004, 12:789-798.
19. Van Gaal LF, Wauters MA, Peiffer FW, Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes 1998, 22(suppl 1):38S-40S.
20. Anselmino M, Bartnik M, Malmberg K, Ryden L. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil 2007, 14:28-36. on behalf of the Euro Heart Survey Investigators.
21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group
22. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) trial. Lancet 1998, 351:1755-1762.
23. Heusser K, Tank J, Diedrich A. Influence of sibutramine treatment on sympathetic vasomotor tone in obese patients. Clin Pharmacol Ther 2006, 79:500-508.
24. Stettler C, Bearth A, Allemann S. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia 2007, 50:186-194.
25. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
26. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-1576.
27. Torp-Pedersen C, Caterson I, Coutinho W. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-2923.